Nicolas Azzopardi

Présentation

Publications

Article dans une revue (29)

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trial Sarah Lobet,David Ternant,Côme Lepage,Karine Le Malicot,Nicolas Azzopardiet al. Biomedicine and Pharmacotherapy, 2026, 198, pp.119242. ⟨10.1016/j.biopha.2026.119242⟩ Article dans une revue hal-05586260v1
Mixed genetic background better recapitulates developmental and psychiatric phenotypes and heterogeneity than inbred C57BL/6J mice Ana Dudas,Ana Novak,Caroline Gora,Emmanuel Pecnard,Nicolas Azzopardiet al. Scientific Reports, 2025, 15 (1), pp.39130. ⟨10.1038/s41598-025-26215-6⟩ Article dans une revue hal-05182452v2
Effect of the social environment on olfaction and social skills in wild-type and a mouse model of autism Caroline Gora,Ana Dudas,Lucas Court,Anil Annamneedi,Gaëlle Lefortet al. Translational Psychiatry, 2024, 14 (1), pp.464. ⟨10.1038/s41398-024-03174-6⟩ Article dans une revue hal-04785377v1
Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients Sarah Lobet,Gilles Paintaud,Nicolas Azzopardi,Christophe Passot,Morgane Cauletet al. Clinical Pharmacokinetics, 2023, 62 (9), pp.1263-1274. ⟨10.1007/s40262-023-01270-2⟩ Article dans une revue hal-04285346v1
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial Sophie Dupuis-Girod,Sophie Rivière,Christian Lavigne,Anne-Emmanuelle Fargeton,Brigitte Gilbert-Dussardieret al. Journal of Internal Medicine, 2023, 294 (6), pp.761-774. ⟨10.1111/joim.13714⟩ Article dans une revue hal-04285361v1
Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX) David Tougeron,Sheik Emambux,Laure Favot,Thierry Lecomte,Ewa Wierzbicka-Hainautet al. OncoImmunology, 2020, 9 (1), pp.1848058. ⟨10.1080/2162402X.2020.1848058⟩ Article dans une revue hal-03149030v1
Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited Amina Bensalem,Denis Mulleman,Gilles Paintaud,Nicolas Azzopardi,Valerie Gouilleux-Gruartet al. Clinical Pharmacokinetics, 2019, ⟨10.1007/s40262-019-00826-5⟩ Article dans une revue hal-02316414v1
CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis Amina Bensalem,Denis Mulleman,Gilles Thibault,Nicolas Azzopardi,Philippe Goupilleet al. British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩ Article dans une revue hal-02376303v1
In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration Thomas Secher,Emilie Dalonneau,Marion Ferreira,Christelle Parent,Nicolas Azzopardiet al. Journal of Controlled Release, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩ Article dans une revue hal-02179896v1
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans David Ternant,Nicolas Azzopardi,William Raoul,Theodora Bejan-Angoulvant,Gilles Paintaud Clinical Pharmacokinetics, In press, ⟨10.1007/s40262-018-0680-3⟩ Article dans une revue hal-01821717v1
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group Mira Tout,Anne-Laure Gagez,Stéphane Lepretre,Valérie Gouilleux-Gruart,Nicolas Azzopardiet al. Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩ Article dans une revue hal-01769807v1
Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice Christophe Arnoult,Guillaume Brachet,Diana Cadena Castaneda,Nicolas Azzopardi,Christophe Passotet al. Journal of Immunology, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩ Article dans une revue hal-02019721v1
Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients Morgane Caulet,Thierry Lecomte,Olivier Bouché,Jérôme Rollin,Valérie Gouilleux-Gruartet al. Clinical Pharmacokinetics, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩ Article dans une revue hal-01769811v1
Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients Yoann Pointreau,Nicolas Azzopardi,David Ternant,Gilles Calais,Gilles Paintaud Therapeutic Drug Monitoring, 2016, 38 (5), pp.567-72. ⟨10.1097/FTD.0000000000000321⟩ Article dans une revue hal-01769813v1
Pharmacokinetics of adalimumab in Crohn’s disease David Ternant,Konstantinos Karmiris,Séverine Vermeire,Celine Desvignes,Nicolas Azzopardiet al. European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩ Article dans une revue hal-01769822v1
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab Jérôme Rollin,Audrey Payancé,Valérie Gouilleux-Gruart,Michelle Boisdron-Celle,Nicolas Azzopardiet al. Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩ Article dans une revue hal-02381189v1
Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia Nicolas Azzopardi,Sophie Dupuis-Girod,David Ternant,Anne-Emmanuelle Fargeton,Isabelle Ginonet al. mAbs, 2015, 7 (3), pp.630 - 637. ⟨10.1080/19420862.2015.1022693⟩ Article dans une revue hal-01769884v1
Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system Laurent Guilleminault,Nicolas Azzopardi,Christophe Arnoult,Julien Sobilo,Virginie Hervéet al. Journal of Controlled Release, 2014, 196, pp.344-354. ⟨10.1016/j.jconrel.2014.10.003⟩ Article dans une revue hal-02376374v1
VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations Virginie Herve,Nathalie Rabbe,Laurent Guilleminault,Flora Paul,Laurène Schlicket al. mAbs, 2014, 6 (6), pp.1638 - 1648. ⟨10.4161/mabs.34454⟩ Article dans une revue hal-01769888v1
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies Christophe Passot,Nicolas Azzopardi,Sylvaine Renault,Nadine Baroukh,Christophe Arnoultet al. mAbs, 2014, 5 (4), pp.614 - 619. ⟨10.4161/mabs.24815⟩ Article dans une revue hal-01769897v1
Influence of plasma exchange on rituximab pharmacokinetics Nicolas Azzopardi,Maud François,Emeline Laurent,Gilles Paintaud,Béatrice Birmelé British Journal of Clinical Pharmacology, 2013, 76 (3), pp.486 - 488. ⟨10.1111/bcp.12167⟩ Article dans une revue hal-01769901v1
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients Nicolas Azzopardi,Thierry Lecomte,David Ternant,Michelle Boisdron-Celle,Friedrich Pilleret al. Clinical Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩ Article dans une revue hal-01769933v1
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients Nicolas Azzopardi,Therry Lecomte,David Ternant,Michele Boisdron-Celle,Friedrich Pilleret al. Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34 Article dans une revue hal-00616314v1
The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors Agnes Maillet,Laurent Guilleminault,Etienne Lemarié,Stephanie Lerondel,Nicolas Azzopardiet al. Pharmaceutical Research, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩ Article dans une revue istex hal-01769936v1
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D. Chu Miow Lin,D. Mulleman,N. Azzopardi,I. Griffoul-Espitalier,J.-P. Valatet al. Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97-98 Article dans une revue hal-00616813v1
Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D Chu Miow Lin,D. Mulleman,N. Azzopardi,G Griffoul-Espitalier,P Valatet al. Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97 - 98. ⟨10.3109/03009740903177745⟩ Article dans une revue hal-01769938v1
An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab Nicolas Ceze,David Ternant,Friedrich Piller,Danielle Degenne,Nicolas Azzopardiet al. Therapeutic Drug Monitoring, 2009, 31 (5), pp.597-601 Article dans une revue hal-00521871v1
Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab Agnes Maillet,Laurent Guilleminault,Nicolas Azzopardi,Jerome Montharu,Laurent Vecellioet al. Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600 Article dans une revue hal-00616858v1
Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis Juliette Thariat,Nicolas Azzopardi,Frederic Peyrade,Vincent Launay-Vacher,Jose Santiniet al. Journal of Clinical Oncology, 2008, 26 (25), pp.4223-4225 Article dans une revue hal-00616934v1

Poster de conférence (1)

Relationship between rituximab concentration and autoantibody levels in anti-neutrophil cytoplasmic antibody associated vasculitis A Bensalem,D Ternant,N. Azzopardi,G. Paintaud,V Gouilleux-Gruartet al. EULAR 2019, Jun 2019, MADRID, Spain Poster de conférence hal-02149477v1

Pré-publication, Document de travail (3)

The insertion of Neomycin cassette impairs maternal and social behaviors in Arc/Arg3.1 knock-out mice Ana Dudas,Emilia Caire,Abdurahman Hassan a Kuku,Nicolas Azzopardi,Anil Annamneediet al. 2025 Pré-publication, Document de travail hal-05056624v1
Hormone-regulated dynamics of mRNA distribution on ribosomes in Sertoli cells Xavier Leray,Julia Morales,Aurélie Tréfier,Kelly León,Thomas Bourquardet al. 2025 Pré-publication, Document de travail hal-04869030v1
Effect of the social environment on olfaction and social skills in WT and mouse model of autism Caroline Gora,Ana Dudas,Lucas Court,Anil Annamneedi,Gaëlle Lefortet al. 2023 Pré-publication, Document de travail hal-04312827v1